Prevalence of Thrombophilia in Male Patients
Thrombophilia is detected in approximately 28.5% of male patients presenting with venous thromboembolism, with strong thrombophilia (homozygous mutations, natural anticoagulant deficiencies, or multiple disorders) found in 6.6% of cases 1.
Prevalence by Clinical Context
The prevalence of thrombophilia in males varies significantly based on age and whether the VTE event was provoked or unprovoked:
Males Aged 40-60 Years
- Unprovoked VTE: Thrombophilia detected in 35.7% of cases, with strong thrombophilia in 12.5% 1
- Provoked VTE: Thrombophilia detected in 19.5% of cases, with strong thrombophilia in 4.9% 1
This data reveals a critical clinical pattern: men with unprovoked events in middle age have nearly double the thrombophilia prevalence compared to those with provoked events, making the distinction between provoked and unprovoked events essential for risk stratification.
Males Over 60 Years
A common pitfall is assuming older age excludes significant thrombophilia risk—the data shows that males over 60 actually have a higher prevalence of strong thrombophilia (9.1%) compared to younger patients (4.7%), challenging traditional age-based testing exclusion criteria 1.
Genetic Factors Contributing to Prevalence
The most common genetic predispositions in the general population include 2:
- Factor V Leiden (FVL): Found in 90-95% of all patients with activated protein C resistance
- **Factor II c.*97G>A (Prothrombin mutation)**: Second most common genetic thrombophilia
- Combined genetic factors: Present in about 25% of screening populations without family history and up to 63% of familial cases
Protein C, protein S, and antithrombin III deficiencies account for approximately 5-10% of patients with thrombosis 2.
Key Risk Predictors in Males
Male sex itself is an environmental risk factor for VTE 2, which partially explains the baseline prevalence. Two factors significantly increase the likelihood of positive thrombophilia testing in males:
- Family history of VTE (including superficial vein thrombosis): OR 1.80; 95% CI 1.71-2.77 1
- Proximal location of deep vein thrombosis: OR 1.94; 95% CI 1.25-3.02 1
Clinical Implications
Despite the 28.5% overall prevalence, approximately 50% of first-time VTE cases are apparently unprovoked 2, meaning thrombophilia testing will be negative in the majority of male VTE patients even when indicated. The decision to test should focus on whether results would alter management decisions, not simply on the statistical likelihood of finding thrombophilia 3.
The high prevalence of strong thrombophilia in males over 60 (9.1%) and in middle-aged men with unprovoked VTE (12.5%) suggests that rigid age-based exclusion criteria for testing may miss clinically significant thrombophilias 1.